<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">30924702</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1557-1246</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>24</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of attention disorders</Title>
          <ISOAbbreviation>J Atten Disord</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD.</ArticleTitle>
        <Pagination>
          <StartPage>348</StartPage>
          <EndPage>358</EndPage>
          <MedlinePgn>348-358</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1177/1087054719836159</ELocationID>
        <Abstract>
          <AbstractText><b>Objective:</b> The objective of this study is to evaluate efficacy and safety of SPN-812 (extended-release viloxazine) for ADHD in children aged 6 to 12 years. <b>Method:</b> In an 8-week study, 222 participants were randomized to placebo or SPN-812 100, 200, 300, or 400 mg/day. Measurements included ADHD Rating Scale (RS)-IV total score and Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scores. Safety assessments included laboratory and electrocardiogram (ECG) measurements, suicidality monitoring (Columbia-Suicide Severity Rating Scale), and adverse event (AE) reporting. <b>Results:</b> Significant improvements in ADHD-RS-IV total score were observed for 200, 300, and 400 mg dose groups versus placebo (<i>p</i> &lt; .05; effect size [ES] = 0.547, 0.596, and 0.623). CGI-I score for the 300 mg group and CGI-S score for all SPN-812 groups except for 100 mg improved significantly (<i>p</i> &lt; .05) versus placebo. The most frequent AEs (≥15%) were somnolence, headache, and decreased appetite. <b>Conclusion:</b> SPN-812 significantly reduced the severity of ADHD symptoms and was well tolerated. The efficacy and safety of SPN-812 are being investigated in Phase III trials.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Johnson</LastName>
            <ForeName>Janet K</ForeName>
            <Initials>JK</Initials>
            <AffiliationInfo>
              <Affiliation>Formerly at Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liranso</LastName>
            <ForeName>Tesfaye</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saylor</LastName>
            <ForeName>Keith</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>NeuroScience, Inc., Herndon, VA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tulloch</LastName>
            <ForeName>Gabriela</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Formerly at Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adewole</LastName>
            <ForeName>Toyin</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schwabe</LastName>
            <ForeName>Stefan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nasser</LastName>
            <ForeName>Azmi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Findling</LastName>
            <ForeName>Robert L</ForeName>
            <Initials>RL</Initials>
            <AffiliationInfo>
              <Affiliation>Johns Hopkins University, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Kennedy Krieger Institute, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Newcorn</LastName>
            <ForeName>Jeffrey H</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>03</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Atten Disord</MedlineTA>
        <NlmUniqueID>9615686</NlmUniqueID>
        <ISSNLinking>1087-0547</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5I5Y2789ZF</RegistryNumber>
          <NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="Y">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000697" MajorTopicYN="Y">Central Nervous System Stimulants</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014745" MajorTopicYN="Y">Viloxazine</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">ADHD</Keyword>
        <Keyword MajorTopicYN="Y">attention deficit/hyperactivity disorder</Keyword>
        <Keyword MajorTopicYN="Y">nonstimulant</Keyword>
        <Keyword MajorTopicYN="Y">viloxazine</Keyword>
      </KeywordList>
      <CoiStatement><b>Declaration of Conflicting Interests:</b> The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J.K.J. is a former employee of Supernus Pharmaceuticals, Inc.; T.L. is an employee of Supernus Pharmaceuticals, Inc.; K.S. received clinical trial research support from Otsuka and Supernus Pharmaceuticals, Inc. and serves as a consultant and advisory board member for Supernus Pharmaceuticals, Inc.; G.T. is a former employee of Supernus Pharmaceuticals, Inc.; T.A. is an employee of Supernus Pharmaceuticals, Inc.; S.S. is an employee of Supernus Pharmaceuticals, Inc.; A.N. is an employee of Supernus Pharmaceuticals, Inc.; R.L.F. discloses past or present relationships with the following organizations in the past 24 months: Research support, and/or consultant, and/or speaker’s bureau for Aevi, Akili, Alcobra, Amerex, American Academy of Child &amp; Adolescent Psychiatry, Bracket, Daiichi Sankyo, ePharmaSolutions, Forest, Genentech, Ironshore, KemPharm, Lundbeck, U.S. National Institutes of Health, Neurim, Nuvelution, Otsuka, PCORI, Pfizer, Physicians Postgraduate Press, Roche, Shire, Sunovion, Supernus Pharmaceuticals, SyneuRx, Teva, Tris, TouchPoint, Validus; and received royalties from American Psychiatric Press and Sage. J.H.N. discloses the following relationships: Akili Interactive (consultant), Alcobra (consultant), Arbor (consultant), Cingulate Therapeutics (consultant), Enzymotec (consultant, research support), KemPharm (consultant), Lundbeck (consultant, research support), Medice (consultant), NLS Pharma (consultant), Pfizer (consultant), Rhodes (consultant), Shire (consultant, research support), Sunovion (consultant), and Supernus Pharmaceuticals Inc. (consultant). He received research support from Enzymotec, Lundbeck, and Shire.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30924702</ArticleId>
        <ArticleId IdType="pmc">PMC6939319</ArticleId>
        <ArticleId IdType="doi">10.1177/1087054719836159</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Adesman A. R. (2001). The diagnosis and management of attention-deficit/hyperactivity disorder in pediatric patients. Primary Care Companion to the Journal of Clinical Psychiatry, 3(2), 66-77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC181164</ArticleId>
            <ArticleId IdType="pubmed">15014618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington, DC: Author.</Citation>
        </Reference>
        <Reference>
          <Citation>
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Washington, DC: American Psychiatric Publishing.</Citation>
        </Reference>
        <Reference>
          <Citation>
Briars L., Todd T. (2016). A review of pharmacological management of attention-deficit/hyperactivity disorder. Journal of Pediatric Pharmacology and Therapeutics, 21, 192-206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4956327</ArticleId>
            <ArticleId IdType="pubmed">27453697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Busner J., Targum S. D. (2007). The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry, 4(7), 28-37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2880930</ArticleId>
            <ArticleId IdType="pubmed">20526405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Catala-Lopez F., Hutton B., Nunez-Beltran A., Page M. J., Ridao M., Macías Saint-Gerons D., . . . Moher D. (2017). The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PLoS ONE, 12(7), e0180355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5507500</ArticleId>
            <ArticleId IdType="pubmed">28700715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Childress A., Tran C. (2016). Current investigational drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opinion on Investigational Drugs, 25, 463-474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26814173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Clemow D. B., Bushe C. J. (2015). Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients. Journal of Psychopharmacology, 29, 1221-1230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26349559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Connor D. F., Arnsten A. F., Pearson G. S., Greco G. F. (2014). Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents. Expert Opinion on Pharmacotherapy, 15, 1601-1610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24992513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Danckaerts M., Sonuga-Barke E. J., Banaschewski T., Buitelaar J., Döpfner M., Hollis C., . . . Coghill D. (2010). The quality of life of children with attention deficit/hyperactivity disorder: A systematic review. European Child &amp; Adolescent Psychiatry, 19, 83-105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3128746</ArticleId>
            <ArticleId IdType="pubmed">19633992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Danielson M. L., Bitsko R. H., Ghandour R. M., Holbrook J. R., Kogan M. D., Blumberg S. J. (2018). Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016. Journal of Clinical Child &amp; Adolescent Psychology, 47, 199-212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5834391</ArticleId>
            <ArticleId IdType="pubmed">29363986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Guy W. (1976). ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health, U.S. Department of Health, Education, and Welfare.</Citation>
        </Reference>
        <Reference>
          <Citation>
Harpin V. A. (2005). The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Archives of Disease in Childhood, 90(Suppl. 1), i2-i7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1765272</ArticleId>
            <ArticleId IdType="pubmed">15665153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hervas A., de Santos T., Quintero J., Ruíz-Lázaro P. M., Alda J. A., Fernández-Jaén A., Ramos-Quiroga J. A. (2016). Delphi consensus on attention deficit hyperactivity disorder (ADHD): Evaluation by a panel of experts. Actas Españolas de Psiquiatría, 44(6), 231-243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27906414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hervas A., Huss M., Johnson M., McNicholas F., van Stralen J., Sreckovic S., . . . Robertson B. (2014). Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: A randomized, controlled, phase III trial. European Neuropsychopharmacology, 24, 1861-1872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25453486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Huss M., Chen W., Ludolph A. G. (2016). Guanfacine extended release: A new pharmacological treatment option in Europe. Clinical Drug Investigation, 36(1), 1-25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4706844</ArticleId>
            <ArticleId IdType="pubmed">26585576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Huss M., Sikirica V., Hervas A., Newcorn J. H., Harpin V., Robertson B. (2016). Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: Efficacy following prior methylphenidate treatment. Neuropsychiatric Disease and Treatment, 112, 1085-1101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4863687</ArticleId>
            <ArticleId IdType="pubmed">27226715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Johnson J. K., Saylor K., Brittain S. T., Tulloch G., Liranso T. (2015, October
26-31). Double-blind, randomized, placebo-controlled study of immediate-release viloxazine (SPN-812 IR) as a novel non-stimulant therapy in adults with attention-deficit/hyperactivity disorder (ADHD). Poster presented at American Academy of Child and Adolescent Psychiatry, San Antonio, TX.</Citation>
        </Reference>
        <Reference>
          <Citation>
Johnson J. K., Saylor K., Brittain S. T., Tulloch G., Liranso T. (2017, October
23-28). A double-blind, placebo-controlled, dose-ranging study of extended-release viloxazine (SPN-812 ER) in children with ADHD. Abstract presented at American Academy of Child and Adolescent Psychiatry, Washington, DC.</Citation>
        </Reference>
        <Reference>
          <Citation>
Kelly R. (2010). Calculating clinically significant change: Applications of the Clinical Global Impressions (CGI) Scale to evaluate client outcomes in private practice. Clinical Psychologist, 14, 107-111.</Citation>
        </Reference>
        <Reference>
          <Citation>
Peasgood T., Bhardwaj A., Biggs K., Brazier J. E., Coghill D., Cooper C. L., . . . Sonuga-Barke E. J. (2016). The impact of ADHD on the health and well-being of ADHD children and their siblings. European Child &amp; Adolescent Psychiatry, 25, 1217-1231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5083759</ArticleId>
            <ArticleId IdType="pubmed">27037707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shire US Inc. (2017). INTUNIV® (guanfacine) extended-release tablets, for oral use, prescribing information. Lexington, MA: Author.</Citation>
        </Reference>
        <Reference>
          <Citation>
Sheehan D. V., Sheehan K. H., Shytle R. D., Janavs J., Bannon Y., Rogers J. E., . . . Wilkinson B. (2010). Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). Journal of Clinical Psychiatry, 71, 313-326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20331933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement Management, Wolraich M., Brown L., Brown R. T., DuPaul G., . . . Visser S. (2011). ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 128, 1007-1022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4500647</ArticleId>
            <ArticleId IdType="pubmed">22003063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
U.S. Department of Justice. (n.d.). List of controlled substances. Retrieved from https://www.deadiversion.usdoj.gov/schedules</Citation>
        </Reference>
        <Reference>
          <Citation>
Zhang S., Faries D. E., Vowles M., Michelson D. (2005). ADHD Rating Scale IV: Psychometric properties from a multinational study as a clinician-administered instrument. International Journal of Methods in Psychiatric Research, 14, 186-201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6878282</ArticleId>
            <ArticleId IdType="pubmed">16395872</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
